Entheogenix Biosciences is a biotech company formed as a partnership between ATAI Life Sciences and Cyclica. The aim of the company is to develop the next generation of psychedelic-inspired drugs for mental health.
Entheogenix Biosciences
From pitchbook: “Developer of pharmaceutical compounds created with an aim to change the paradigm in which mental health disorders are treated. The company focuses on design and synthesize of new chemical entities from psychoactive seed small molecule compounds, striving to offer innovative medicines for effective treatment of mental health disorders.“
Key Staff
- Srinivas Rao – Co-founder & CEO (CSO of ATAI)
- Naheed Kurji – Co-founder & Board Member (CEO of Cyclica)
- Florian Brand – Co-founder & Board Member (CEO of ATAI)
- Glenn Short – CSO
- Robert Perni – Consultant
- Simon Seibold – Operations Lead
News
- EntheogeniX Biosciences gets going (Medium, February 2020)
- ATAI Life Sciences and Cyclica Launch Joint Venture to Revolutionize Drug Development for Mental Health Disorders (press release, November 2019)
- Cyclica & ATAI Life Sciences form Entheogenix Biosciences for Mental Health Treatment Research (Paul Hastings, November 2019)
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates